Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Achieving Its Operational and Business Plan Objectives
Lexaria just completed dosing for its second human clinical study, HYPER-H21-2 The study sought to understand the human response to Lexaria’s DehydraTECH 2.0-enabled CBD The company also announced that its DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the United States Lexaria also expanded its intellectual property portfolio with the allowance of its second patent in Japan It also received US$3,817,643 from warrant exercises, proceeds from which will be used to advance the company’s research and development program and for its general corporate purposes Lexaria Bioscience (NASDAQ: LEXX) has been making incredible strides in 2021 as…